Q-omics provides the consensus-scored BTF3P6 profile across patient tissues and cancer cell-line models. BTF3P6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, BTF3P6 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, BTF3P6 RNA expression shows 10,863 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, BLCA, and LSCC as cancer lineages where BTF3P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P6 survival associations across molecular data types. BTF3P6 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P6 RNA expression–survival associations across cancer types. High BTF3P6 expression shows unfavorable associations in COAD, KIRC, MESO, BLCA, LGG and UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify COAD as the clearest survival context for BTF3P6 RNA expression.
This table summarizes BTF3P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P6 shows lower tumor expression in THCA and higher tumor expression in BLCA, KIRC, STAD, COAD and LUSC. The BLCA box plot shows higher BTF3P6 RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p = .013).
This table shows molecular features associated with BTF3P6 in patient tissues and cancer cell lines. In patient samples, BTF3P6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
